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Introduction
Most forms of chronic renal disease tend to progress
to end-stage glomerulosclerosis and tubulointerstitial
fibrosis (1). Tubulointerstitial fibrosis is preceded by
marked infiltration of the tubulointerstitium by
inflammatory mediators, interstitial fibroblast pro-
liferation, and tubular dilation, resulting finally in
increased ECM protein deposition in the tubular
interstitium (2). In most renal diseases the degree of
tubulointerstitial changes observed in the early stage
of different nephropathies predicts the long-term
outcome of renal function (3).
Unilateral ureteral obstruction (UUO) in mice or rats
is a well-established nonimmune inflammatory experi-
mental model resulting in tubulointerstitial fibrosis in
the obstructed kidney. In humans, chronic but also
acute ureteral obstruction occurs in different kidney dis-
eases at all ages. Most of the time it is congenital in new-
borns or induced by trauma or prostatic hypertrophy in
adults. Without an appropriate treatment, these
obstructive uropathies may progress to end-stage renal
disease. In acute ureteral obstruction, the relief of the
obstruction is obviously the most efficient therapy (4).
However, this is not always feasible, and when detected
too late, even relief of the obstruction does not stop the
progression of tubulointerstitial fibrosis. Indeed, in a
model of temporary UUO in the neonatal rat, despite the
relief of the obstruction, growth of the postobstructed
kidney was impaired and interstitial fibrosis was
observed leading to renal insufficiency in adulthood (5).
In animal models of UUO it has been shown that
angiotensin-converting enzyme (ACE) inhibitors and, to
a lesser extent, angiotensin type I (AT1) receptor antago-
nists, prevent the progression of tubulointerstitial fibro-
sis (6, 7). ACE converts angiotensin I into angiotensin II
and degrades bradykinin (8). Moreover, it has been found
that ACE has a higher affinity for bradykinin than for
angiotensin I (9) and that ACE inhibition significantly
increases bradykinin concentrations (10).
A number of experimental and clinical studies have
shown the therapeutic relevance of ACE inhibitors in
slowing the progression of various renal diseases
(11–13). Although in these studies it has been strong-
ly suggested that bradykinin could participate active-
ly in the beneficial effects of ACE inhibitors, no func-
tional studies of the role of bradykinin and its G
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protein–coupled B2 receptor in renal tubulointersti-
tial fibrosis have been reported. That is the reason why
we studied the functional role of the bradykinin B2
receptor in the development of tubulointerstitial
fibrosis caused by UUO.
We report here that renal tubulointerstitial fibrosis
induced by UUO is significantly higher in B2 receptor
knockout (B2–/–) mice than in wild-type (B2+/+) mice.
Confirming this observation, UUO-induced tubu-
lointerstitial fibrosis was reduced in transgenic rats
overexpressing the tissue kallikrein gene (expressing
increased endogenous bradykinin). It was found that
B2–/– mice have a lower plasminogen activator (PA)
(comprising urokinase-type PA [uPA] and tissue-type
PA [tPA]) activity associated with a decrease in metal-
loproteinase (MMP-2) activity, which can explain the
increased UUO-induced tubulointerstitial fibrosis in
B2–/– mice. The ability of bradykinin to increase PA
activity was confirmed in primary culture renal proxi-
mal tubular cells. The present study demonstrates, we
believe for the first time in vivo, that bradykinin B2
receptor activation plays a protective role in renal
tubulointerstitial fibrosis.
Methods
Animals. B2–/– mice were generously provided by F. Hess
and T. MacNeil (Merck & Co. Inc., Rahway, New Jersey,
USA) (14). B2–/– mice were originally on a mixed genet-
ic background (J129sv × C57Bl/6J). We have back-
crossed (ten times) the B2–/– mice to C57Bl/6J and have
therefore used C57Bl/6J as control mice. Microsatellite
analyses confirmed the C57Bl/6J genetic background
of the mice by backcrossing generated B2–/– mice
(Nucleis, Angers, France). Furthermore, the mice are
housed in a pathogen-free environment. Transgenic
rats overexpressing the human tissue kallikrein gene,
TGR(hKLK1), and their transgene negative littermates
were generated as described previously (15).
Experimental protocols. Male mice or rats at the age of
8 weeks were used in these experiments, ten mice or five
rats in each group. The unilateral ureteral ligation was
performed as follows: under oxygen-isoflurane anes-
thesia, through a longitudinal, left abdominal incision,
the ureter was exposed and ligated with a 6/0 nylon
(4/0 for rats) thread at the uretero-pelvic junction. In
sham operations, the ureter was exposed but not ligat-
ed and repositioned. Mice and rats were maintained on
a standard mouse or rat chow and tap water. All treat-
ments were initiated 1 day before obstruction and con-
tinued throughout the time of obstruction (3 hours to
14 days). B2 receptor antagonist HOE-140 (500 µg/kg;
HOECHST) was injected daily by one subcutaneous
injection. At the end of the different protocols, mice or
rats were sacrificed, and the kidneys were removed and
divided in different parts according to the different
protocols employed. All experiments reported were
conducted in accordance with the NIH guide for the
care and use of laboratory animals and were approved
by a local animal care and use committee.
Immunohistochemistry. Kidneys were fixed in Carnoy’s
solution, dehydrated, embedded in paraffin, and then
sectioned at 3 µm and subjected to the following analy-
ses. Once deparaffinized and rehydrated, the kidney
sections were stained with Sirius red and periodic acid-
Schiff (PAS) to evaluate interstitial collagen deposition
and tubular atrophy, respectively. Immunohistochem-
ical studies for the detection of fibronectin, collagen
type I, III, IV, macrophages, the proliferating cell
nuclear antigen (PCNA), and α-smooth muscle actin
(α-SMC) for the detection of myofibroblasts were per-
formed as follows. Deparaffinized sections were incu-
bated with 3% hydrogen peroxide to block the endoge-
nous peroxidase activity. The sections were then
incubated for 1 hour at room temperature in a humid-
ified atmosphere with the following primary Ab’s: goat
polyclonal anti-human fibronectin (SC-6953; Santa
Cruz Biotechnology Inc., Santa Cruz, California, USA),
rabbit polyclonal anti-rat collagen type I (AB755;
Chemicon International, Temecula, California, USA),
rabbit anti-human collagen III and IV (T59105R and
T59106R, respectively; Interchim, Montluçon, France),
the rat mAb to mouse F4/80 (RM2900; Caltag Labora-
tories Inc., Burlingame, California, USA) for
macrophage detection, and the monoclonal mouse
anti-human α-SMC (DAKO EPOS method, U7033;
DAKO S.A., Trappes, France). For fibronectin and col-
lagen I, the sections were sequentially processed with
the goat (fibronectin) or rabbit (collagen I) ABC Stain-
ing System (Santa Cruz Biotechnology Inc.), which uses
3,3′-diaminobenzidine as chromogen. For the visuali-
zation of collagen III and IV and F4/80, the DAKO
Envision System was used (DAKO S.A.). Cell prolifera-
tion was assessed by detection of PCNA using the
Zymed PCNA staining kit (Zymed Laboratories Inc.,
San Francisco, California, USA). Sections were coun-
terstained with hematoxylin. For all samples, negative
controls for the immunohistochemical procedures
included substitution of the primary Ab with nonim-
mune sera. The presence of myofibroblasts was ana-
lyzed on PCNA adjacent sections to be able to compare
both localizations. Glomeruli and vasculature were
excluded from the evaluation in the present study.
Histomorphometric analysis. Analyses were performed
by an operator unaware of the origin of each kidney
section. Under a light microscope (Nikon Eclipse 600)
at ×200 magnification, 20 nonoverlapping fields (to
obtain around 90% of the kidney section) per kidney
section were captured with a numeric camera (Cool
SNAP; RS Photometrics, Tucson, Arizona, USA) con-
nected to the microscope. Quantitative analysis of the
pictures was performed by using the Adobe PhotoShop
5.5 software, which allows counting of the pixels
stained specifically (red for Sirius red and brown for the
immunohistochemical studies). The results are given
in percentage of specific colored pixels per total num-
ber of pixels of the 20 fields, representing thus the sur-
face occupied by the analyzed marker. For PCNA and
α-SMC detection, marked cells were counted.
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RNA preparation and Northern blot analysis. Total RNA
from snap-frozen kidney sections was extracted using
the RNeasy Midi kit (QIAGEN Inc., Valencia, Califor-
nia, USA). Glyoxal and dimethyl sulfoxide denatured
RNA (20 µg) was separated on a phosphate-buffered
1% agarose gel and transferred under vacuum with a
blotting device on a positively charged polyamide
membrane (Schleicher & Schuell Inc., Keene, New
Hampshire, USA). The cDNA probes (between 200
and 350 bp) were obtained by RT-PCR, verified by
sequencing, and radiolabeled with [α-32P]dATP using
the Strip-EZ DNA Kit (Ambion Inc., Austin, Texas,
USA). Hybridization was performed in Ultrahyb
buffer (Ambion Inc.). Densitometric analysis was per-
formed as described (16).
Primary culture of mouse renal proximal tubular cells.
Mouse proximal tubular cells were obtained by an
extension of a method described previously (17).
Briefly, after removal of the kidneys, the kidney cor-
tex was minced in HBSS at 4°C and incubated two
times for 20 minutes at 37°C with 0.2 mg/ml collage-
nase solution supplemented by 1 mg/ml BSA. After
centrifugation (5 minutes at 135 g), the pellet was
washed two times with HBSS and two times with
HBSS containing 1% BSA. To obtain homogenous
populations of nephron segments, the mixture of
tubules was resuspended in 42% Percoll made isoton-
ic with concentrated (10×) Krebs Henseleit buffer
(KHB), pH 7.3 — 1.18 M NaCl, 47 mM KCl, 100 mM
HEPES, 200 mM cyclamic acid, 1.26 mM MgSO4, 11.4
mM KH2PO4, and 50 mM glucose — and centrifuged
(34,900 g for 30 minutes at 4°C). The F4 layer, con-
taining the proximal tubules, was suspended in cul-
ture medium (DMEM/HAM F12) supplemented with
5% FCS, 10 µg/ml insulin, 5 mM transferrin, 10 ng/ml
EGF, 0.1 µM dexamethasone, and 5 µg/ml triodothy-
ronin, and plated at a concentration of 1.6 mg of pro-
tein per 100 mm2 of a Petri dish coated with collagen.
The proximal tubular origin and epithelial cell type
was confirmed by positive alkaline phosphatase activ-
ity and cytokeratin staining (data not shown). West-
ern blot analysis and calcium mobilization experi-
ments on proximal tubular cells were performed as
described previously (18). The B2 receptor Ab (mouse
mAb B40820) used in the Western blot experiment
(dilution 1/500) was from Transduction Laboratories
(Lexington, Kentucky, USA).
Kidney protein extraction for enzyme activity measure-
ments and zymography. For PA activity determination,
one-sixth of a kidney is rapidly transferred into a 1.5-
ml reaction tube containing 150 µl of ice-cold buffer
A (13 mM sodium citrate, 0.33 M sodium acetate, pH
3.9) and manually homogenized on ice for 10 seconds
using a potter’s device (1.5 ml Piston Pellet; Treff AG,
Degersheim, Switzerland), followed by centrifugation
for 5 minutes at 12,000 g at 4°C. Supernatant (100 µl)
is then added to 5 µl of 20% acetic acid, gently mixed,
and stored at –80°C until further use. For MMP-2
and MMP-9 zymography, one-sixth of a kidney is
transferred into 150 µl of ice-cold buffer (10 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA) in a 1.5-ml reaction tube and treated as
described for PA activity, but without addition of 5 µl
of 20% acetic acid. Protein concentrations were deter-
mined by the Bio-Rad Protein Assay (Bio-Rad Labo-
ratories, Ivry sur Seine, France).
PA activity and zymography. PA activity present in cell
supernatants and kidney extracts was determined
using a chromogenic assay (spectrolyse/fibrin;
Biopool International, Umea, Sweden). This kit con-
tains a specific EPA stimulator, Desafib-x. Samples
were diluted in 0.9% of NaCl before analysis. MMP-2
and -9 activities were determined using zymography.
Cell supernatant (20 µl) or kidney extract (25 µg) with
nonreducing SDS sample buffer was loaded onto
8–10% SDS-polyacrylamide gels containing 1 mg/ml
gelatin. After electrophoresis, gels were soaked two
times for 20 minutes in 2.5% (vol/vol) of Triton X-100
at room temperature and incubated overnight at
37°C in activation buffer (10 mM Tris-HCl, pH 7.5,
1.25% Triton X-100 [vol/vol], 5 mM CaCl2, and 1 µM
ZnCl2). The following day, gels were stained for 3
hours with 0.25% (wt/vol) Coomassie brilliant blue in
a mixture of methanol/acetic acid/water (50/10/40
vol/vol/vol) and destained in the same mixture with-
out Coomassie brilliant blue.
Statistical analysis. All the data are expressed as mean
plus or minus SD. Statistical analyses were per-
formed using SPSS software (SPSS Science, Chicago,
Illinois, USA). ANOVA with post hoc Tukey alpha
test was performed for comparison between the dif-
ferent groups. P values less than 0.05 were considered
statistically significant.
Results
UUO-induced tubulointerstitial fibrosis is significantly higher
in B2–/– mice. Interstitial collagen deposition was stud-
ied histomorphometrically in Sirius red–stained renal
sections of B2–/– and B2+/+ mice as an index of the
fibrotic response to UUO.
Interstitial fibrosis increased progressively from day
1 to day 14 and became significantly different between
the two mouse strains 3 days after obstruction (Figure
1a). At day 5, the difference between B2–/– and B2+/+
mice was the largest (Figure 1b), with an interstitial
collagen expression that occupied 35% ± 4% and 
17% ± 2% of the kidney sections, respectively. Since
this difference was smaller at day 14, and extreme tis-
sue damage was observed at day 14, all further experi-
ments were carried out 5 days after obstruction. No
significant difference between both mice strains in
tubulointerstitial fibrosis of sham-operated and the
contralateral kidney was observed (data not shown).
PAS and hematoxylin-stained kidney sections showed
an increase in tubular damage characterized by tubu-
lar dilation, atrophy, and hypercellularity in the
obstructed kidneys, but without differences between
B2–/– and B2+/+ mice (not shown).
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Further evidence of B2 receptor–mediated reduction of tubu-
lointerstitial fibrosis. To verify that the effect observed in
B2–/– mice was effectively due to the absence of B2
receptor activation, we have performed UUO either on
transgenic rats exhibiting increased endogenous
bradykinin expression caused by overexpression of the
human tissue kallikrein gene TGR(hKLK1) (15) or on
B2+/+ mice treated with a specific kinin-B2 receptor
antagonist (HOE-140).
TGR(hKLK1) rats displayed significantly less UUO-
induced tubulointerstitial fibrosis than their non-
transgenic littermates (Figure 1c), which was abolished
by HOE-140 treatment. Furthermore, HOE-140 also
increased UUO-induced interstitial fibrosis in B2+/+
mice (Figure 1d). B2–/– mice, the transgenic rat model,
and pharmacological treatment thus strongly suggest
that in both mice and rats, bradykinin B2 receptor acti-
vation reduces renal fibrosis.
Identification of ECM compounds. We next determined,
using immunostaining, expression of ECM com-
pounds known to be increased after UUO (Figure 2).
After 5 days of UUO, the expression of fibronectin and
collagen I, III, and IV was increased in both mouse
strains. However, only collagen type III and IV expres-
sion was significantly higher in the B2–/– mice (Figure
2, b and c, respectively).
How does bradykinin modify tubulointerstitial fibrosis?
Analysis of mRNA expression and enzyme activity. Current
evidence supports the idea that fibrosis of several organs,
including the kidney, is a consequence of the disturbance
of the balance between ECM synthesis and degradation.
Using Northern blotting, we first studied mRNA
expression of key proteins in UUO: ECM proteins
(fibronectin and collagen I, III, and IV), TGF-β, mono-
cyte chemoattractant peptide-1 (MCP-1), and osteo-
pontin. UUO increased expression of all mRNA tested
without difference between B2+/+ and B2–/– mice, except
for collagen IV mRNA expression, which was higher in
B2–/– mice (Figure 3).
The two main systems involved in ECM degradation
are the matrix metalloproteinases and the plasminogen
activation system, which are closely interlinked (19).
We thus investigated these degrading systems and
found that UUO clearly increased mRNA expression of
matrix metalloproteinases MMP-2 and MMP-9 and
their respective inhibitors TIMP-1 and TIMP-2 (Figure
4), as well as the mRNA expression of tPA, uPA, and the
PA inhibitor type 1 (PAI-1) (Figure 4a). However, no dif-
ference in mRNA expression was found between B2+/+
and B2–/– mice.
Since it has been reported that bradykinin is a
potent stimulus for tPA secretion (20), we have meas-
ured total PA activity in sham-operated and obstruct-
ed kidneys of both mice strains. In preliminary exper-
iments we have observed that the specific stimulator
of tPA) increased PA activity by only three times (not
shown), while it is described to increase tPA activity by
300 times. In a control reaction in which we added
purified tPA to kidney extracts, Desafib-X increased
by 240 ± 15 times PA activity, showing that the lack of
increase in PA activity in kidney extracts is probably
caused by a low tPA concentration. Non-Desafib-
X–stimulated PA activity is thus a mixture of tPA and
uPa activity. All reported activities in this study are
non-Desafib-X–stimulated total PA activities. UUO
induced an increase in PA activity in kidneys of both
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Figure 1
Quantitative analysis of UUO-induced renal inter-
stitial collagen expression in B2–/– knockout mice,
kallikrein transgenic rats, and B2 receptor antago-
nist–treated wild-type mice. (a) Collagen expression
in obstructed kidneys from B2+/+ and B2–/– mice
after different periods of ureteral obstruction 
(3 hours to 14 days). Data are expressed as the 
mean ± SD percentage of the interstitial area
stained; n = 10; *P < 0.05 compared with respective
B2+/+ (same time of obstruction). (b) Representa-
tive photographs of Sirius red–stained renal sections
of 5 day–obstructed and sham-operated B2+/+ and
B2–/– mice. Original magnification ×400. (c) Colla-
gen expression in kidneys from 5 day–obstructed
and sham-operated kallikrein transgenic and con-
trol (Sprague Dawley) rats. One group was treated
with HOE-140. n = 5 per group. *P < 0.05 com-
pared with sham-operated rats; ‡P < 0.05 com-
pared with UUO kallikrein transgenic rats without
HOE-140. (d) Collagen expression in kidneys from
5 day–obstructed B2+/+ mice treated with saline only
or with saline containing HOE-140 at 500 µg/kg/d;
n = 10 per group. Data expressed as the mean ± SD
percentage of the interstitial area stained; *P < 0.05
compared to without HOE-140.
B2–/– and B2+/+ mice. However, there was a significant-
ly lower PA activity in the obstructed kidneys of B2–/–
mice (Figure 4b), whereas no difference between the
two mouse strains in PA activity was detected in the
sham-operated kidneys.
This decrease in PA activity in obstructed kidneys
from B2–/– mice was paralleled with a lower MMP-2
activity in kidneys of B2–/– mice as assessed by zymog-
raphy (Figure 4c); no difference between B2+/+ and B2–/–
mice was observed for MMP-9 (data not shown).
Since the previous in vivo experiments were based
on the difference between the presence or absence
of B2 receptors, we have used primary cultures of
renal proximal tubular cells obtained from kidneys
of B2+/+ mice to verify if bradykinin via B2 receptor
activation was able to stimulate PA activity (Figure
5a). Interestingly, we were not able to detect
bradykinin-induced PA activity in tubular cells cul-
tivated in standard culture medium, whereas lovas-
tatin or TGF-β (positive controls) were able to stim-
ulate PA activity. However, pretreatment of the
tubular cells with proinflammatory factors (TNF-α
and IFN-γ) resulted in a bradykinin-induced PA
activity, which was blocked by the specific B2 antag-
onist (HOE-140). The increased bradykinin-
induced PA activity after pretreatment of cells by
the proinflammatory factors was not due to
increased bradykinin B2 receptor expression (West-
ern blot, Figure 5b) or coupling (calcium mobiliza-
tion, Figure 5c). Pretreatment with a nitric oxide
inhibitor did not block the bradykinin-induced PA
activity (Figure 5a). Bradykinin treatment of proxi-
mal renal tubular cells obtained from B2–/– mice did
not display increased PA activity under the condi-
tions described above (not shown).
Taken together, these data strongly suggest that
bradykinin is reducing UUO-induced tubulointer-
stitial fibrosis by increasing the activity of enzymes
involved in ECM degradation and by decreasing col-
lagen IV mRNA expression.
Macrophage infiltration is decreased in B2–/– mice. One
of the early events in the development of tubuloin-
terstitial fibrosis is tubulointerstitial inflammation
and, more precisely, interstitial macrophage infil-
tration. In the sham-operated kidney and in the
contralateral unobstructed kidney (not shown), a
low level of macrophages was present in the tubu-
lointerstitium, but no significant difference was
found between both mouse strains. As expected,
UUO induced a significant increase in interstitial
macrophage infiltration, and, surprisingly, this
macrophage infiltrate was found to be significant-
ly lower in the obstructed kidney of B2–/– mice com-
pared with B2+/+ mice (Figure 6a).
Cell proliferation is not modified in B2–/– mice. Cell pro-
liferation also being a hallmark of obstructive
nephropathy, we evaluated renal cell proliferation by
immunostaining for PCNA. A very small number of
PCNA-positive cells were found in the sham-operat-
ed kidney and in the contralateral unobstructed kidney
(not shown), but UUO clearly increased both tubular
and interstitial PCNA staining in the obstructed kid-
neys of both mice groups, however, without difference
between B2–/– and B2+/+ mice (Figure 6b). Using an Ab
that recognizes α-SMC, and thus myofibroblasts, on
PCNA adjacent sections (Figure 6c), it was found that
the majority of proliferating cells identified with PCNA
were myofibroblasts, with no difference between the
two mouse strains.
The Journal of Clinical Investigation | August 2002 | Volume 110 | Number 3 375
Figure 2
(a–d) Upper panels: representative light micrographs of immunodetec-
tion of collagen I, III, IV, and fibronectin expression within kidney sec-
tions from B2+/+ and B2–/– mice either sham-operated or UUO for 5
days. Lower panels, corresponding quantitative analysis of collagen I,
III, IV, and fibronectin expression. Data are expressed as the mean ± SD
percentage of the interstitial area stained; n = 10; *P < 0.05 compared
with respective sham-operated mice. ‡P < 0.05 compared with obstruct-
ed B2+/+ mice. Original magnification ×400.
Discussion
It is known that bradykinin is involved in the control of
a wide range of physiological functions, including car-
diovascular homeostasis (regulation of systemic blood
pressure and organ blood flow), water and electrolyte
transport, and pain-transmitting mechanisms (21).
Besides these well-known physiological effects, brady-
kinin is involved in inflammation, and increasing clin-
ical evidence suggests that bradykinin could play a role
in the beneficial effect of ACE inhibitors in diabetic
nephropathy and cardiovascular pathologies (22–24).
In the present study we describe, we believe for the first
time and in vivo, by using both genetically engineered
animals and pharmacological tools, a bradykinin B2
receptor–dependent renal antifibrotic effect.
The bradykinin B2 receptor and ECM accumulation. We
have shown that B2-receptor activation in vivo reduced
UUO-induced tubulointerstitial fibrosis. Renal fibro-
sis was more severe in B2–/– than in B2+/+ mice and more
severe in B2+/+ mice treated with a B2 receptor antago-
nist. In contrast, transgenic rats overexpressing
kallikrein (thus expressing increased bradykinin levels)
displayed less UUO-induced tubulointerstitial fibrosis,
an effect that was blocked by B2 receptor antagonist
administration. These observations are consistent with
the antifibrotic effect of kallikrein overexpression on
cardiac fibrosis (15) and with the observation that
bradykinin levels are reduced in the obstructed rat kid-
ney (25). By using immunohistochemistry, it was
observed that the differences in tubulointerstitial fibro-
sis observed between B2–/– and B2+/+ mice were mainly
caused by differences in collagen III and IV expression.
Collagen IV was the ECM protein that made up the
largest part of the kidney sections compared with the
other collagens. This is consistent with previous stud-
ies reporting a preferential accumulation of collagen IV
in this obstructive nephropathy model (7).
ECM accumulation in pathological states is believed
to result from an imbalance between both synthesis
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Figure 3
Northern-blot analysis of mRNA expression of total RNA of proteins
involved in ECM formation and degradation and the matrix itself
obtained from 5 day–obstructed and sham-operated kidneys of B2+/+
and B2–/– mice. (a) Representative autoradiograms. (b) Adjacent his-
tograms are the mean densitometric values (± SD) after analysis of
the Northern blots and normalization with GAPDH; n = 10.*P < 0.05
compared with respective sham-operated mice. ‡P < 0.05 compared
with B2+/+ UUO mice.
Figure 4
Expression and activity of the renal plasminogen system in 5
day–obstructed and sham-operated B2+/+ and B2–/– mice. (a) North-
ern blot mRNA expression analysis. Representative autoradiograms
of tPA, uPA, PAI-1, and GAPDH are shown. Adjacent histograms are
the mean densitometric values (± SD) after analysis of the Northern
blots (n = 10) and normalization with GAPDH. (b) PA activity. (c)
Analysis of matrix MMP-2 activity by zymography. Quantification of
MMP-2 activity by densitometric analysis is shown in the histogram.
*P < 0.05 compared with respective sham-operated mice. ‡P < 0.05
compared with B2+/+ UUO mice. L, latent; A, active MMP-2.
and degradation (19). We analyzed how bradykinin B2
receptor activation can reduce ECM expression by
studying both ECM synthesis and degradation.
First, mRNA expression of 14 proteins that have been
shown to be involved/increased in this model (2) was
studied. We observed in the obstructed kidney a net
increase in mRNA expression of fibronectin, collagen
I, III, and IV, TGF-β, MCP-1, osteopontin, MMP-2 and
-9, TIMP-1 and -2, as well as the plasminogen activation
system (PAI-1, tPA, and uPA). However, no significant
difference between B2–/– and B2+/+ mice was observed
except for collagen IV mRNA expression that was sig-
nificantly higher in obstructed kidneys of the B2–/–
mice. The latter is consistent with the observed
increased collagen IV protein expression. In vitro,
bradykinin treatment either increased or decreased
ECM production, depending on the cell type used.
Bradykinin increased extracellular collagen synthesis
by rat vascular smooth muscle cells (increased colla-
gen I mRNA expression and gene-reporter activity,
increased TIMP-1 protein expression, and increased
TGF-β protein expression) (26). On the other hand, in
cultured cardiac fibroblasts, bradykinin decreased
ECM production (collagen I, III, and fibronectin
mRNA expression) by a mechanism probably involving
nitric oxide production (27). Besides our in vivo study,
no data are available on the effect of bradykinin on col-
lagen IV (mRNA or protein) expression.
Second, we observed that B2 receptor activation
increased PA activity. PA activity was significantly
reduced in obstructed kidneys of B2–/– mice, and in
primary culture, proximal tubular cells obtained from
B2+/+ mice pretreated with inflammatory mediators,
bradykinin via B2 receptor activation increased PA
activity. In our system, PA activity is composed of
both tPA and uPA activity. Although, to our knowl-
edge, nothing is known about the effect of bradykinin
on uPA activity, bradykinin was found to be one of the
most potent stimuli of tPA release in the circulation
in both rodents (20) and human vasculature (28). In
this context it is important to stress that we deter-
mined PA activity and not tPA or uPA release as
described above. How bradykinin modifies this PA
activity and release is not known. In our study the
decreased PA activity in B2–/– mice was not due to
increased PAI-1 mRNA expression, since we observed
the same increase in both mouse strains, which is con-
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Figure 5
(a) Effect of bradykinin (24 hours at 0.1µM) on PA activity from
primary culture proximal tubular cells pretreated (24 hours) with
TNF-α (150 U/ml) and IFN-γ (500 U/ml) (boxed part of the figure)
or non-pretreated. TGF-β, 10 ng/ml; HOE-140, 0.1 µM; NG-nitro-
L-arginine methyl ester (L-NAME), 0.5 mM; lovastatine, 5 µM. (b)
Western blot of B2 receptor (B2R) expression. (c) Increase in intra-
cellular calcium ([Ca2+]i) following bradykinin (0.1 µM) stimula-
tion (time of stimulation 5 minutes). Values are mean ± SEM of five
different experiments. *P < 0.05 compared with control cells. Rep-
resentative blots or traces are shown.
Figure 6
Immunohistochemical analysis of interstitial macrophage- (a),
PCNA- (b), and α-SMC–positive (c) cell expression in kidney sections
from obstructed (5 day ) and sham-operated kidneys of B2+/+ and
B2–/– mice. Data are expressed as the mean ± SD; n = 10; *P < 0.05
compared with respective sham-operated mice. ‡P < 0.05 compared
with B2+/+ UUO mice.
sistent with an earlier report that bradykinin induces
tPA but not PAI-1 release in human vasculature (28).
In human vasculature bradykinin-induced tPA release
was nitric oxide and cyclooxygenase independent (29).
We found in primary culture proximal tubular cells
from B2+/+ mice that bradykinin-induced PA activity
was nitric oxide independent. Another possibility for
PA activation/secretion by bradykinin might be a
direct interaction between the B2 receptor and 
the PAs. This was shown recently for the NMDA 
(N-methyl-D-aspartate) receptor, which was found to
directly interact with tPA. NMDA treatment induced
tPA release from the NMDA receptor, which resulted
in tPA-dependent cleavage of the NR1 subunit of the
NMDA receptor, thereby increasing the receptor’s
activity (30). Such a direct interaction with the B2
receptor might explain the rapid tPA release upon
bradykinin treatment in humans (29).
Third, decreased PA activity in B2–/– mice coincided
with decreased MMP-2 activity. Collagen IV is the pref-
erential substrate for MMP-2 (31). Plasmin can trans-
form metalloproteinases from their latent to their active
forms. Furthermore, uPA seems to be able to activate
MMP-2 by activation of a membrane-bound metallo-
proteinase (19). The paralleled decrease in PA and
MMP-2 activity related to increased ECM expression
thus suggests a role for the B2 receptor/PA activ-
ity/MMP-2 activity cascade in ECM degradation.
Finally, the increased collagen IV mRNA expression
can also be the result of the decreased PA activity in
B2–/– mice since this will result in increased fibrin dep-
osition that stimulates collagen accumulation (19).
Bradykinin and macrophage infiltration. Ureteral
obstruction is primarily a nonimmune stimulus, but
results in an interstitial immune infiltrate by the pro-
duction of tubular-derived chemotactic factors as early
as 4 hours after the onset of obstruction (32, 33). This
infiltrate (mainly macrophages and lymphocytes)
releases cytokines and chemokines, which can induce
collagen synthesis by fibroblasts and cause further
injury of tubules (2). Surprisingly, kidneys of UUO
B2–/– mice exhibited a significantly lower number of
interstitial macrophages than B2+/+ mice. This reduced
number of macrophages in the tubulointerstitium of
obstructed kidneys of B2–/– compared with B2+/+ mice,
accompanied by increased tubulointerstitial ECM
deposition, seems to contradict the role of this early
event in the development of renal fibrosis after ureter-
al obstruction. It is, however, consistent with the well-
described proinflammatory actions of bradykinin,
mainly characterized by its vasodilatory effects and
leukocyte accumulation (34, 35). In general, decreased
interstitial macrophage infiltration is correlated to
reduced tubulointerstitial fibrosis in the UUO model.
There are, however, quite a few exceptions in the UUO
model in which interstitial macrophage infiltration is
not related to or has different effects on the degree of
tubulointerstitial fibrosis. A reduction of around 50%
of infiltrating macrophages in the UUO model result-
ed in a reduction of 10% and 25% of tubulointerstitial
fibrosis in AT1 receptor-deficient mice (36) and treat-
ment with a chemokine receptor antagonist (37),
respectively, showing that the degree of macrophage
infiltration was not correlated to the same degree of
fibrosis. In another study it was shown that an AT2
receptor antagonist reduced interstitial fibrosis with-
out an effect on interstitial macrophage infiltration
(38). Furthermore, in our study reduced interstitial
macrophage infiltration was not related to reduced
activated fibroblast infiltration, which was observed in
studies where reduced macrophage infiltration is
accompanied by reduced interstitial fibrosis (37, 39).
The absence of a positive correlation between de-
creased macrophage infiltration and decreased tubu-
lointerstitial fibrosis in our study might thus have at
least two origins: (a) the absence of differences in acti-
vated fibroblast infiltration between B2+/+ and B2–/–
mice, and (b) the reduction of about 35% of infiltrat-
ing macrophages in B2–/– mice, which does not com-
pensate the reduced PA activity in this strain, thus
resulting in increased tubulointerstitial fibrosis com-
pared with B2+/+ mice.
Taken together, the results of this study show that
bradykinin B2 receptor activation in vivo reduces
UUO-induced tubulointerstitial fibrosis most likely by
increasing the activity of a PA/MMP-2 cascade. These
observations favor a potential role of bradykinin in the
antifibrotic effects of ACE inhibitors.
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